세계의 벨리스타(Benlysta) 시장 보고서 : 역학, 파이프라인 분석, 시장 인사이트 및 예측(2025년)

Benlysta Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

US $ 4,490 ￦ 6,290,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,091,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,893,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

벨리스타(Benlysta) 시장 규모는 향후 수년간 급성장이 전망됩니다. 2029년에는 CAGR 11%로 성장할 전망이며, 36억 7,220만 달러로 성장이 예측됩니다. 예측 기간 동안 성장의 배경에는 정밀 의료에 대한 수요 증가, 희귀 질환에 대한 의식 증가, 생물학적 단제 요법의 이용 확대, 면역학에 대한 투자 증가, 정부 지원 증가 등이 있습니다. 예측 기간 주요 동향으로는 면역학 진보, 혁신적인 약물 전달 시스템, 연구기관과의 연계, 전략적 파트너십, 의약품 개발에서의 AI 및 기계학습 등을 들 수 있습니다.

자가면역 질환의 이환율 증가는 향후 벨리스타(Benlysta) 시장의 성장을 가속할 것으로 예측됩니다. 자가면역 질환은 면역계가 실수로 건강한 세포, 조직, 장기를 공격하는 질환입니다. 이러한 질환의 유병률 상승은 진단 방법 개선, 환경적 유인, 라이프 스타일 변화, 유전적 요인, 고령화 등의 요인에 의한 것입니다. 벤리스타는 과도한 면역반응에 관여하는 B림프구자극인자(BLyS) 단백질을 표적으로 함으로써 자가면역 질환, 특히 전신성 에리테마토데스(SLE)의 관리에 도움을 줍니다. 이를 통해 유해한 B세포의 생존율을 떨어뜨리고 건강한 조직을 공격하는 것을 막아 질환 활동성을 조절할 수 있습니다. 예를 들어 국민건강회의는 2024년 3월에 자가면역 질환은 미국에서 약 5,000만 명에게 영향을 미치고 있다고 보고하고 있지만, 진단상의 과제에서 진짜 수는 더 많을 수 있습니다. 자가면역 질환은 증가하고 있으며, 연간 3%에서 12%의 증가를 시사하는 연구도 있습니다. 더불어 국립의료도서관에 따르면 자가면역 질환의 세계적 발생률은 매년 19.1% 증가하고 유병률은 매년 12.5% 증가하고 있습니다. 따라서 자가면역 질환 환자의 증가가 벨리스타의 수요를 촉진하고 있습니다.

또한 헬스케어 지출 증가도 벨리스타(Benlysta) 시장의 확대에 기여할 것으로 예상되고 있습니다. 헬스케어 지출은 병원 치료, 의약품, 의료 관리 등 의료 서비스에 대한 모든 지출을 커버하고 있습니다. 고령화, 만성질환 부담 증가, 의료기술 발전 등으로 의료비는 증가 추세입니다. 게다가 인플레이션 및 의료 수요 증가가 비용을 끌어올리고 있습니다. 그 결과 의료 지출의 증가는 낭창과 같은 만성 자가면역 질환 치료에 대한 투자를 증가시켜 생물제제의 수요 증가로 이어짐으로써 벨리스타(Benlysta) 시장을 지탱하고 있습니다. 예를 들어, 국가통계국은 2024년 5월에 영국의 헬스케어 지출은 2022년의 0.9% 증가에 대해 2022-2023년 5.6% 증가했다고 보고했습니다. 2023년 영국의 헬스케어 지출은 약 3,176억 3,000만 달러(2,920억 파운드)에 달했습니다. 이처럼 헬스케어 지출의 성장이 벨리스타(Benlysta) 시장을 밀어올리고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 바이오의약품 시장에서의 제품 특성

• 분자 유형
• 투여 경로(ROA)
• 작용기전(MOA)
• 안전성 및 유효성

제4장 시장 동향 및 전략

제5장 시장 : 금리, 인플레이션, 지정학적 요인, 신형 코로나와 그 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제6장 세계의 성장 분석 및 전략 분석 프레임워크

• 세계의 벨리스타(Benlysta) : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인 및 억제요인)
• 최종 이용 산업의 분석
• 세계의 벨리스타(Benlysta) 시장 : 성장률 분석
• 세계의 벨리스타(Benlysta) 시장 실적 : 규모 및 성장(2019-2024년)
• 세계의 벨리스타(Benlysta) 시장 예측 : 규모 및 성장(2024-2029년, 2034년)
• 세계의 벨리스타(Benlysta) : 전체 시장 규모(TAM)

제7장 세계의 가격 분석 및 예측

제8장 시장 세분화

• 세계의 벨리스타(Benlysta) 시장 : 투여 경로별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 정맥내(IV)
• 피하(SC)
• 세계의 벨리스타(Benlysta) 시장 : 질환별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 전신성 홍반성 루푸스(SLE)
• 루푸스 신염(LN)
• 기타 관련 증상
• 세계의 벨리스타(Benlysta) 시장 : 최종 사용자별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 병원
• 클리닉
• 재택 케어
• 전문 약국

제9장 세계의 임상적응증 역학

• 약제의 부작용
• 임상적응증의 발병률 및 유병률

제10장 지역별 및 국가별 분석

• 세계의 벨리스타(Benlysta) 시장 : 지역별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 세계의 벨리스타(Benlysta) 시장 : 국가별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 한국 시장

제17장 서유럽 시장

제18장 영국 시장

제19장 독일 시장

제20장 프랑스 시장

제21장 동유럽 시장

제22장 북미 시장

제23장 미국 시장

제24장 캐나다 시장

제25장 남미 시장

제26장 중동 시장

제27장 아프리카 시장

제28장 경쟁 구도 및 기업 프로파일

• 벨리스타(Benlysta) 시장 : 경쟁 구도
• 벨리스타(Benlysta) 시장 : 기업 프로파일
  • GlaxoSmithKline plc

제29장 세계 시장 : 파이프라인 분석

제30장 세계 시장 경쟁 벤치마킹 및 대시보드

제31장 주요 인수합병(M&A)

제32장 최근 시장 동향

제33장 시장의 잠재력이 높은 국가, 부문 및 전략

• 벨리스타(Benlysta) 시장(2029년) : 새로운 기회를 제공하는 국가
• 벨리스타(Benlysta) 시장(2029년) : 새로운 기회를 제공하는 부문
• 벨리스타(Benlysta) 시장(2029년) : 성장 전략
  • 시장 동향에 의한 전략
  • 경쟁 전략

제34장 부록

AJY

영문 목차

영문목차

Benlysta is a biologic medication known as belimumab, primarily used for the treatment of systemic lupus erythematosus (SLE), an autoimmune disease. It works by targeting and inhibiting the BLyS protein, which reduces the survival of B cells, helping to decrease disease activity and prevent organ damage. Benlysta is administered through intravenous infusion or subcutaneous injection.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main methods of benlysta administration are intravenous (IV) and subcutaneous (SC). IV administration involves delivering the medication directly into a vein, ensuring rapid absorption into the bloodstream. The clinical indications for Benlysta include systemic lupus erythematosus (SLE), lupus nephritis (LN), and other conditions. Benlysta is used by various end users, including hospitals, clinics, home care settings, and specialty pharmacies, ensuring broad accessibility and flexibility in treatment.

The benlysta market research report is one of a series of new reports from The Business Research Company that provides benlysta market statistics, including benlysta industry global market size, regional shares, competitors with a benlysta market share, detailed benlysta market segments, market trends and opportunities, and any further data you may need to thrive in the benlysta industry. This benlysta market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The benlysta market size is expected to see rapid growth in the next few years. It will grow to $3,672.2 million in 2029 at a compound annual growth rate (CAGR) of 11%. The growth in the forecast period can be attributed to growing demand for precision medicine, growth in rare disease awareness, growing use of biologic monotherapies, rising investments in immunology, and rising government support. Major trends in the forecast period include advances in immunology, innovative drug delivery systems, collaboration with research institutions, strategic partnerships, and AI and machine learning in drug development.

The growing incidence of autoimmune diseases is anticipated to drive the growth of the benlysta market in the future. Autoimmune diseases are conditions where the immune system mistakenly attacks healthy cells, tissues, and organs. The rising prevalence of these diseases is attributed to factors such as better diagnostic methods, environmental triggers, lifestyle changes, genetic factors, and an aging population. Benlysta helps manage autoimmune diseases, particularly systemic lupus erythematosus (SLE), by targeting the B-lymphocyte stimulator (BLyS) protein, which is involved in the overactive immune response. This helps reduce the survival of harmful B cells, preventing them from attacking healthy tissues and controlling disease activity. For example, the National Health Council reported in March 2024 that autoimmune diseases affect around 50 million people in the United States, though the true number may be higher due to diagnostic challenges. Autoimmunity is increasing, with some studies suggesting an annual rise of 3% to 12%. Additionally, according to the National Library of Medicine, the global incidence of autoimmune diseases increases by 19.1% annually, with prevalence rising by 12.5% each year. Therefore, the increase in autoimmune disease cases is fueling the demand for benlysta.

The growth in healthcare spending is also expected to contribute to the expansion of the benlysta market. Healthcare expenditure covers all spending on medical services, including hospital care, pharmaceuticals, and healthcare administration. It is rising due to an aging population, the growing burden of chronic diseases, and advancements in medical technology. In addition, inflation and increasing healthcare demands are driving up costs. As a result, rising healthcare spending supports the benlysta market by increasing investments in treatments for chronic autoimmune diseases such as lupus, leading to higher demand for biologic therapies. For example, the Office for National Statistics reported in May 2024 that healthcare spending in the UK grew by 5.6% between 2022 and 2023, compared to a 0.9% increase in 2022. In 2023, UK healthcare expenditure reached approximately $317.63 billion (£292 billion). Thus, the growth in healthcare spending is boosting the benlysta market.

A significant trend in the benlysta market is the development of innovative products, such as autoinjectors, which improve treatment accessibility and convenience, especially for pediatric SLE patients. Autoinjectors are devices that allow patients to quickly and easily administer medication, often for chronic conditions or emergencies. In May 2024, GlaxoSmithKline announced that the FDA approved the Benlysta (belimumab) autoinjector for pediatric patients aged 5 years and older with SLE. This approval provides the first at-home treatment option for children who need belimumab, enabling subcutaneous administration and eliminating the need for regular clinical visits. The autoinjector enhances convenience and flexibility for caregivers, addressing the significant impact lupus has on children, including higher rates of organ damage.

The key company operating in the benlysta market is GlaxoSmithKline plc

North America was the largest region in the benlysta market in 2024. The regions covered in benlysta report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the benlysta market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The benlysta market consists of sales of products such as immune system modulators, infusion equipment and biologic drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Benlysta Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on benlysta market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for benlysta ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The benlysta market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Route Of Administration: Intravenous (IV); Subcutaneous (SC)
• 2) By Clinical Indication: Systemic Lupus Erythematosus (SLE); Lupus Nephritis (LN); Other Related Conditions
• 3) By End Users: Hospitals; Clinics; Home Care Settings; Specialty Pharmacies
• Companies Mentioned: GlaxoSmithKline plc
• Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Benlysta Market Characteristics

3. Benlysta Market Biologic Drug Characteristics

• 3.1. Molecule Type
• 3.2. Route Of Administration (ROA)
• 3.3. Mechanism Of Action (MOA)
• 3.4. Safety And Efficacy

4. Benlysta Market Trends And Strategies

5. Benlysta Market -Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

6. Global Benlysta Growth Analysis And Strategic Analysis Framework

• 6.1. Global Benlysta PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 6.2. Analysis Of End Use Industries
• 6.3. Global Benlysta Market Growth Rate Analysis
• 6.4. Global Benlysta Historic Market Size and Growth, 2019 - 2024, Value ($ Million)
• 6.5. Global Benlysta Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Million)
• 6.6. Global Benlysta Total Addressable Market (TAM)

7. Global Benlysta Pricing Analysis & Forecasts

8. Benlysta Market Segmentation

• 8.1. Global Benlysta Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• Intravenous (IV)
• Subcutaneous (SC)
• 8.2. Global Benlysta Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• Systemic Lupus Erythematosus (SLE)
• Lupus Nephritis (LN)
• Other Related Conditions
• 8.3. Global Benlysta Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• Hospitals
• Clinics
• Home Care Settings
• Specialty Pharmacies

9. Global Benlysta Epidemiology Of Clinical Indications

• 9.1. Drug Side Effects
• 9.2. Incidence And Prevalence of Clinical Indications

10. Benlysta Market Regional And Country Analysis

• 10.1. Global Benlysta Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 10.2. Global Benlysta Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

11. Asia-Pacific Benlysta Market

• 11.1. Asia-Pacific Benlysta Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Benlysta Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 11.3. Asia-Pacific Benlysta Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 11.4. Asia-Pacific Benlysta Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

12. China Benlysta Market

• 12.1. China Benlysta Market Overview
• 12.2. China Benlysta Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Million
• 12.3. China Benlysta Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Million
• 12.4. China Benlysta Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Million

13. India Benlysta Market

• 13.1. India Benlysta Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 13.2. India Benlysta Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 13.3. India Benlysta Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

14. Japan Benlysta Market

• 14.1. Japan Benlysta Market Overview
• 14.2. Japan Benlysta Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 14.3. Japan Benlysta Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 14.4. Japan Benlysta Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

15. Australia Benlysta Market

• 15.1. Australia Benlysta Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 15.2. Australia Benlysta Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 15.3. Australia Benlysta Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

16. South Korea Benlysta Market

• 16.1. South Korea Benlysta Market Overview
• 16.2. South Korea Benlysta Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 16.3. South Korea Benlysta Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 16.4. South Korea Benlysta Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

17. Western Europe Benlysta Market

• 17.1. Western Europe Benlysta Market Overview
• 17.2. Western Europe Benlysta Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 17.3. Western Europe Benlysta Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 17.4. Western Europe Benlysta Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

18. UK Benlysta Market

• 18.1. UK Benlysta Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 18.2. UK Benlysta Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 18.3. UK Benlysta Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

19. Germany Benlysta Market

• 19.1. Germany Benlysta Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 19.2. Germany Benlysta Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 19.3. Germany Benlysta Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

20. France Benlysta Market

• 20.1. France Benlysta Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 20.2. France Benlysta Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 20.3. France Benlysta Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

21. Eastern Europe Benlysta Market

• 21.1. Eastern Europe Benlysta Market Overview
• 21.2. Eastern Europe Benlysta Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 21.3. Eastern Europe Benlysta Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 21.4. Eastern Europe Benlysta Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

22. North America Benlysta Market

• 22.1. North America Benlysta Market Overview
• 22.2. North America Benlysta Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 22.3. North America Benlysta Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 22.4. North America Benlysta Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

23. USA Benlysta Market

• 23.1. USA Benlysta Market Overview
• 23.2. USA Benlysta Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 23.3. USA Benlysta Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 23.4. USA Benlysta Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

24. Canada Benlysta Market

• 24.1. Canada Benlysta Market Overview
• 24.2. Canada Benlysta Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 24.3. Canada Benlysta Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 24.4. Canada Benlysta Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

25. South America Benlysta Market

• 25.1. South America Benlysta Market Overview
• 25.2. South America Benlysta Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 25.3. South America Benlysta Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 25.4. South America Benlysta Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

26. Middle East Benlysta Market

• 26.1. Middle East Benlysta Market Overview
• 26.2. Middle East Benlysta Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 26.3. Middle East Benlysta Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 26.4. Middle East Benlysta Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

27. Africa Benlysta Market

• 27.1. Africa Benlysta Market Overview
• 27.2. Africa Benlysta Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 27.3. Africa Benlysta Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 27.4. Africa Benlysta Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

28. Benlysta Market Competitive Landscape And Company Profiles

• 28.1. Benlysta Market Competitive Landscape
• 28.2. Benlysta Market Company Profiles
  • 28.2.1. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

29. Global Benlysta Market Pipeline Analysis

• 29.1. High Level Clinic Trail Information

30. Global Benlysta Market Competitive Benchmarking And Dashboard

31. Key Mergers And Acquisitions In The Benlysta Market

32. Recent Developments In The Benlysta Market

33. Benlysta Market High Potential Countries, Segments and Strategies

• 33.1 Benlysta Market In 2029 - Countries Offering Most New Opportunities
• 33.2 Benlysta Market In 2029 - Segments Offering Most New Opportunities
• 33.3 Benlysta Market In 2029 - Growth Strategies
  • 33.3.1 Market Trend Based Strategies
  • 33.3.2 Competitor Strategies

34. Appendix

• 34.1. Abbreviations
• 34.2. Currencies
• 34.3. Historic And Forecast Inflation Rates
• 34.4. Research Inquiries
• 34.5. The Business Research Company
• 34.6. Copyright And Disclaimer